ANALYSES OF HEALTHCARE RESOURCE UTILIZATION (HCRU) IN CHECKMATE 141, A PHASE 3 STUDY OF NIVOLUMAB VERSUS INVESTIGATOR'S CHOICE (IC) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) PLATINUM-REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

被引：0
|
作者：
DeRosa, M. [1 ]
Cocks, K. [2 ]
Taylor, F. [1 ]
Bobiak, S. [3 ]
Garcia, Juarez A. [3 ]
Shaw, J. W. [3 ]
机构：
[1] Adelphi Values, Boston, MA USA
[2] Adelphi Mill, Bollington, England
[3] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN149
引用
收藏
页码：A113 / A113
页数：1
相关论文
共 50 条
  • [21] Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes
    Haddad, R.
    Blumenschein, G., Jr.
    Fayette, J.
    Guigay, J.
    Colevas, A. D.
    Licitra, L.
    Kasper, S.
    Vokes, E. E.
    Worden, F.
    Saba, N. F.
    Tahara, M.
    Concha-Benavente, F.
    Monga, M.
    Lynch, M.
    Li, L.
    Shaw, J. W.
    Gillison, M. L.
    Harrington, K. J.
    Ferris, R. L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC
    Even, C.
    Daste, A.
    Saada-Bouzid, E.
    Fayette, J.
    Kaminsky-Forrett, M-C.
    Zanetta, S.
    Prevost, A.
    Lefebvre, G.
    Borel, C.
    Cupissol, D.
    Huguet, F.
    Delord, J-P.
    Rotllan, N. Baste
    Delaye, J.
    Jallut, I.
    Vintonenko, N.
    Bourhis, J.
    Guigay, J.
    Texier, M.
    Auperin, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 380 - 380
  • [23] Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141
    Ferris, Robert L.
    Blumenschein, George R.
    Fayette, Jerome
    Guigay, Joel
    Colevas, A. Dimitrios
    Licitra, Lisa
    Harrington, Kevin J.
    Kasper, Stefan
    Vokes, Everett E.
    Even, Caroline
    Worden, Francis
    Saba, Nabil F.
    Docampo, Lara Carmen Iglesias
    Haddad, Robert
    Rordorf, Tamara
    Kiyota, Naomi
    Tahara, Makoto
    Lynch, Mark
    Jayaprakash, Vijayvel
    Li, Li
    Gillison, Maura L.
    CANCER RESEARCH, 2018, 78 (13)
  • [24] Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the phase 3 Checkmate 141 study
    Haddad, Robert
    Ferris, Robert L.
    Blumenschein, George
    Fayette, Jerome
    Guigay, Joel
    Colevas, Alexander D.
    Licitra, Lisa
    Kasper, Stefan
    Vokes, Everett E.
    Worden, Francis
    Saba, Nabil F.
    Tahara, Makoto
    Monga, Manish
    Lynch, Mark
    Zhu, Jin
    Shaw, James W.
    Gillison, Maura L.
    Harrington, Kevin
    CANCER RESEARCH, 2017, 77
  • [25] Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)
    Zenda, Sadamoto
    Onozawa, Yusuke
    Boku, Narikazu
    Fida, Yoshiyuki
    Ebihara, Mitsuru
    Onitsuka, Tetsuro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (07) : 477 - 481
  • [26] Paclitaxel plus cetuximab versus nivolumab for patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
    Kodama, Hiroyuki
    Kadowaki, Shigenori
    Ishizuka, Yasunobu
    Wakabayashi, Munehiro
    Sakakida, Tomoki
    Honda, Kazunori
    Masuishi, Toshiki
    Narita, Yukiya
    Taniguchi, Hiroya
    Ando, Masashi
    Kishikawa, Toshihiro
    Terada, Hoshino
    Beppu, Shintaro
    Nishikawa, Daisuke
    Suzuki, Hidenori
    Hanai, Nobuhiro
    Muro, Kei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (03) : 480 - 488
  • [27] Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups
    Ferris, R. L.
    Blumenschein, G. R.
    Fayette, J.
    Guigay, J.
    Colevas, A. D.
    Licitra, L.
    Harrington, K.
    Kasper, S.
    Vokes, E. E.
    Even, C.
    Worden, F.
    Saba, N. F.
    Docampo, LCIglesias
    Haddad, R. I.
    Rordorf, T.
    Kiyota, N.
    Tahara, M.
    Lynch, M.
    Li, L.
    Gillison, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1317 - 1317
  • [28] Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC)
    Bauman, Julie E.
    Arias-Pulido, Hugo
    Lee, Sang-Joon
    Considine, Michael
    Fekrazad, M. Houman
    Howard, Jason
    Bishop, Justin A.
    Olson, Garth T.
    Jones, Dennie V.
    Fertig, Elana J.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): Interim analysis on 199 patients-The TOPNIVO study on behalf of the GORTEC and the Unicancer Head & Neck Group.
    Even, Caroline
    Daste, Amaury
    Saada-Bouzid, Esma
    Lefebvre, Gautier
    Fayette, Jerome
    Zanetta, Sylvie
    Kaminsky, Marie-Christine
    Cupissol, Didier
    Prevost, Alain
    Vauleon, Elodie
    Johnson, Alison Claire
    Salas, Sebastien
    Rolland, Frederic
    David, Miruna Timar
    Jallut, Isabelle
    Delaye, Jessy
    Bourhis, Jean
    Guigay, Joel
    Texier, Matthieu
    Auperin, Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
    Bauman, Julie E.
    Arias-Pulido, Hugo
    Lee, Sang-Joon
    Fekrazad, M. Houman
    Ozawa, Hiroyuki
    Fertig, Elana
    Howard, Jason
    Bishop, Justin
    Wang, Hao
    Olson, Garth T.
    Spafford, Michael J.
    Jones, Dennie V.
    Chung, Christine H.
    ORAL ONCOLOGY, 2013, 49 (05) : 461 - 467
12345